Open AccessA Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer
Author(s) -
Thomas E. Stinchcombe,
Amy H. Peterman,
Carrie Lee,
Dominic T. Moore,
Jennifer L. Beaumont,
Daniel W. Bradford,
Kamal Bakri,
Mark P. Taylor,
Jeffrey D. Crane,
Garry Schwartz,
Thomas A. Hensing,
Edwin McElroy,
Harvey B. Niell,
Harry Harper,
Sridhar E. Pal,
Mark A. Socinski
Publication year - 2011
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/1dh7-8a20
Subject(s) - erlotinib , gemcitabine , medicine , oncology , lung cancer , erlotinib hydrochloride , randomized controlled trial , stage (stratigraphy) , cancer , epidermal growth factor receptor , biology , paleontology